Researchers from IMB have won first and third prize at Brisbane’s 2016 HealthHack, held 14-16 October at River City Labs. The winning team, Superfriends Against Superbugs, developed an app to track and map the presence of antibiotic-resistant bacteria and rapidly alert clinicians, so they can limit the spread of bacteria and fight an outbreak in real-time.

In a world-first, IMB's Professor Rob Capon and his team are working with industry and the community to implement a discovery that turns cane toads’ own toxin against them, with real potential to eradicate this long-term pest.

By creating the world’s first molecule bank, IMB scientists are working with industry and institutional partners to crowdsource antibiotic compounds, aiming to seek out new antibiotics and prevent the proliferation of drug-resistant superbugs.

A future where no children suffer deadly brain tumours may be within reach, thanks to the vision of a team of researchers from UQ and generous funding from The Kids’ Cancer Project. This funding will enable IMB postdoctoral researcher Dr Laura Genovesi to develop better treatments – and eventually cures – for these devastating conditions.

IMB researchers have been awarded $4.5 million by the Australian Research Council to lead a range of groundbreaking discovery research projects. The ARC announced funding of more than $37 million today for UQ projects spanning fields as diverse as humanities, behavioural science, biomedicine and frontier technologies.

Protagonist Therapeutics, a clinical-stage biopharmaceutical company founded on IMB research, has won Australian Company of the Year at the AusBiotech Industry Excellence Awards.

IMB research has contributed to UQ's top ranking in the Nature Index 2016 Australia and New Zealand.

The future of medicine could be as simple as nibbling a sunflower seed or drinking a cup of tea, with the opening of a new IMB facility, officially opened the Hon Annastacia Palaszczuk, Queensland Premier and Minister for the Arts.

In a world-first, researchers from UQ IMB and University of Washington (UW) have produced tailor-made peptides – an advance expected to help improve drug design and environmentally-friendly pesticides. The team has designed ultra-stable peptide scaffolds that can be used in a range of biotechnological applications.